

CEBU 2018 – THE APAGE 3RD CLINICAL FORUM ON IBD
20th to 22nd September 2018, Radisson Blu Hotel, Cebu City, Philippines

DAILY PROGRAMME
20th September 2018 (Thursday)

0800 – 1730 **PHILIPPINE SOCIETY OF GASTROENTEROLOGY MIDYEAR CONVENTION**

1810 – 1930 **OPENING DINNER SYMPOSIUM (*Ferring Pharmaceuticals*)**

Chairperson: [Jose Sollano](#)

Safe Treatment of Ulcerative Colitis: Oral Steroid for Topical Effect

[Rupert Leong](#)

1930 – 2000 **OPENING CEREMONY**

- Kentaro Sugano, *President, Asian Pacific Association of Gastroenterology*
- Leticia Guzman, *President, Philippine Society of Gastroenterology*
- Mark Anthony de Lusong, *President, Philippine Society of Digestive Endoscopy*
- Jose Sollano, *Chairman, Local Organizing Committee*
- Choon Jin Ooi, *Organizing Chairman*

DAILY PROGRAMME
21st September 2018 (Friday)

0800 – 0930 **PRE-CONGRESS WORKSHOP 1 (*Concurrent*)**

Endoscopic Therapy in Inflammatory Bowel Disease

0800 – 0805 Introduction [Raja Affendi Raja Ali](#)

0805 – 0835 **Endoscopic Management of Strictures**

0805 – 0815 Balloon dilation

[Raja Affendi Raja Ali](#)

0815 – 0825 Stenting

[Rupert Leong](#)

0825 – 0835 Needle knife stricturotomy

[Alex Leow](#)

0835 – 0900 **Endoscopic Resection of Dysplastic Lesions**

0835 – 0845 Colitis associated dysplasia – When to monitor, when to resect and when to call the surgeons

[Raja Affendi Raja Ali](#)

0845 – 0855 The role of ESD/EMR for colitis associated dysplasia

[Christopher Khor](#)

0855 – 0920 Q & A

0920 – 0930 The Future of Endoscopic Therapy in IBD

[Rupert Leong](#)

0800 – 0930 **PRE-CONGRESS WORKSHOP 2 (*Concurrent*)**

Fecal Microbiota Transplant Workshop

0800 – 0805 Introduction [Michael Kamm](#)

0805 – 0815 Overview and Current Evidence of FMT for IBD

[Rupa Banerjee / Ajit Sood](#)

0815 – 0830 Selecting and Screening the Right Donor

- Rupa Banerjee
0830 – 0850 How to Prepare and Route of Administration
Ajit Sood
- 0850 – 0905 Safety and Complications
David Ong
- 0905 – 0920 Q & A
- 0920 – 0930 The Future of FMT
Michael Kamm
- 0930 – 1030 **MID-MORNING SYMPOSIUM (Johnson & Johnson)**
Chairpersons: *Ernesto Olympia*
IL12/IL23 Pathway in CD – Perspectives from Clinical Practice
Rupert Leong
- 1030 – 1050 **SESSION 1**
Chairpersons: *Jose Sollano / Ida Hilmi*
Disease Modifying Drugs in IBD: The End of the Beginning
Rupert Leong
- 1050 – 1120 **SESSION 2**
Chairpersons: *Choon Jin Ooi / Nazri Mustaffa*
Biologics are Forever – A Tale of Two Experts
Michael Kamm / Vineet Ahuja
- 1120 – 1200 FREE PAPER SESSION (*10 minutes per presentation*)
Chairperson: *David Ong*
Panel of Judges: *Min Hu Chen / Peter Irving / Wai Keung Leung*
- Decreasing Surgical Rates for Crohn's Disease in an Emerging Economy
: Real World Data in the Era of Biologic Therapy
Kee Huat Chuah
- Natural History of Patients with Inflammatory Bowel Disease Who are Positive for
Hepatitis B Core Antibody (anti-HBc) and Requiring Immunosuppressive Therapy
Michael KL Ko
- Prospective validation of CD4+ CD25+ FOXP3+ T-regulatory cells as an immunological
marker to differentiate intestinal tuberculosis from Crohn's disease.
Ritika Rampal
- A preliminary study of Creeping fat in patients with ileo-colonic Crohn's disease
correlates with disease activity and inflammation severity using energy spectral
computed tomography
Zhi Hua Ran

- 1200 – 1300 **LUNCH SYMPOSIUM (*CELLTRION Healthcare*)**
Biosimilar Infliximab: Taking the Lead in a New Era for IBD Management
Chairperson: Jose Sollano
- 1200 – 1205 Welcome and Introduction
- 1205 – 1215 Perceptual evolution on biosimilar of IBD societies
[Jose Sollano](#)
- 1215 – 1230 Key clinical evidence of biosimilar infliximab
[Young Ho Kim](#)
- 1230 – 1240 Sharing on-field experience in Asia: Real world-experience in Singapore
[Choon Jin Ooi](#)
- 1240 – 1250 Sharing on-field experience in Asia: Real world-experience in Malaysia
[Ida Hilmi](#)
- 1250 – 1300 Panel Discussion
- 1300 – 1330 TRADE EXHIBITION/POSTER EXHIBITS
- 1330 – 1445 **SESSION 3**
Assessment and Monitoring of the IBD Patient
Chairpersons: Toshifumi Hibi / Carla Tablante
- 1330 – 1350 Small bowel imaging for Crohn's disease - Capsule, enteroscopy or MRI?
[Zhi Hua Ran](#)
- 1350 – 1410 Comparison between the current fecal markers for IBD
[Katsuyoshi Matsuoka](#)
- 1410 – 1430 How do we treat and follow up patients with mild IBD?
[Michelle Gowans](#)
- 1430 – 1445 Q & A
- 1445 – 1545 **HI-TEA SYMPOSIUM (*A Menarini Asia-Pacific*)**
Chairperson: Sol Alvarez
Optimizing the clinical use of 5-ASA in the treatment of IBD
[Jose Sollano](#)
- 1545 – 1720 **SESSION 4**
Systemic Complications in IBD and IBD Therapy
Chairpersons: Pises Pisespongsa / Murdani Abdullah
- 1545 – 1605 Fertility and pregnancy related issues in IBD
[Nazri Mustafa](#)
- 1605 – 1625 Extracolonic malignancies in IBD
[Wai Keung Leung](#)
- 1625 – 1645 Approach to deranged LFTs in the IBD patient
[Wee Chian Lim](#)
- 1645 – 1705 Management of joint related manifestations in IBD
[Rupa Banerjee](#)
- 1705 – 1720 Q & A
- 1900 – 2200 **FACULTY DINNER (*By Invitation Only*)**

DAILY PROGRAMME
22nd September 2018 (Saturday)

0800 – 0915 **SESSION 5**

Nutrition

Chairpersons: Won Ho Kim / Leticia Guzman

0800 – 0820 Diet and IBD – What your patients want to know

[Vineet Ahuja](#)

0820 – 0840 Probiotics, prebiotics and synbiotics in IBD

[Peter Irving](#)

0840 – 0900 Management of short gut syndrome

[Govind Makharia](#)

0900 – 0915 Q & A

0915 – 1015 **SESSION 6**

**OLYMPUS SYMPOSIUM – Inflammatory Bowel Disease Associated
Dysplasia**

Chairpersons: Taku Kobayashi/ Mark Anthony de Lusong

0915 – 0945 Current guidelines on the surveillance and management of IBD-associated dysplasia

[Christopher Khor](#)

0945 – 1015 Endocytoscopy in IBD – Another paradigm shift in dysplasia surveillance?

[Yuichi Mori](#)

1015 -1045 MID-MORNING SYMPOSIUM (Westmont Pharma)

Chairperson: Jose Sollano

Quality colonoscopy for IBD dysplasia and CRC screening

[Choon Jin Ooi](#)

1045 – 1200 **SESSION 7**

Controversial Issues in IBD Surgery

Chairpersons: Shu Chen Wei / Than Than Aye

1045 – 1105 Prevention and management of post-operative recurrence in Crohn's disease – Do we finally have a standard of care?

[Peter Irving](#)

1105 – 1125 Colectomy versus endoscopic therapy for colitis associated dysplasia

[Pises Pisespongsa](#)

1125 – 1145 Rescue therapy in acute severe colitis – How far can you go?

[Govind Makharia](#)

1145 – 1200 Q & A

1200 – 1300 **LUNCH SYMPOSIUM (Takeda Healthcare)**

Chairperson: Jose Sollano

Choosing a Biologic in IBD

[Michael Kamm](#)

1300 – 1330 POSTER ROUND/BEST POSTER PRESENTATION/TRADE EXHIBITION

1330 – 1445 **SESSION 8**

Emerging Therapies in IBD

Chairpersons: [Khoon Lin Ling](#) / [Lamberto Garcia Jr](#)

1330 – 1350 'Thinking outside the box' – Curcumin and alternative therapies in IBD

[Rupa Banerjee](#)

1350 – 1410 New kids on the block – The role of small molecules in IBD

[Taku Kobayashi](#)

1410 – 1430 Latest advances in the management of perianal fistulas – Beyond biologics

[Peter Gibson](#)

1430 – 1445 Q & A

1445 – 1545 **SESSION 9**

Challenging Cases in IBD (with interactive voting system)

Chairpersons: [Varocha Mahachai](#) / [Karen de Lunas](#)

Expert Panel: [Peter Gibson](#) / [Peter Irving](#) / [Michelle Gowans](#)

1445 – 1515 Case I

1515 – 1545 Case II

1545 – 1700 **SESSION 10**

APAGE/AOCC SYMPOSIUM (with interactive voting system)

Chairpersons: [Rupa Banerjee](#) / [Katsuyoshi Matsuoka](#) / [Evan Ong](#)

1545 – 1605 **Tuberculosis and Biologic Therapy**

- Reactivation of tuberculosis – How do the available biologics measure up?

[Shu Chen Wei](#)

- Consensus guidelines on screening and treatment

[Dong Il Park](#)

1605 – 1625 **Therapeutic Drug Monitoring in IBD**

- Differences in thiopurine pharmacogenetic profile between Asian and Caucasian populations

[Byong Duk Ye](#)

- Consensus guidelines for pharmacogenetics testing and therapeutic drug monitoring

[Sai Wei Chuah](#)

1625 – 1645 **Screening for Infection**

- Screening and prophylaxis for chronic hepatitis B in patients on biologic therapy

[Tadakazu Hisamatsu](#)

- Should screening for EBV be incorporated into our Asian setting?

[Min Hu Chen](#)

1645 – 1700 Q & A

1700 – 1715 **PRIZE AWARD & CLOSING REMARKS**

By: [Jose Sollano](#) & [Choon Jin Ooi](#)

1715-1730 Tea